41 results on '"Foucher, Juliette"'
Search Results
2. HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort
3. Is treatment with Bulevirtide 10 mg useful in poor responder patients to 2 mg? Results from the French multicenter early access program
4. Two-dimensional versus one-dimensional transient elastography: benefits of ultrasound imaging-based processing for liver stiffness measurements
5. Quantitative ultrasound for liver steatosis assessment: benefits of measurements over a large two-dimensional region of interest on the performance of image-brightness-based parameters
6. Repeated noninvasive liver biopsy surrogate LIVERFASt correlates with BMI and liver enzyme improvements
7. Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide
8. Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings
9. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis
10. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort
11. Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease
12. Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness
13. Liver stiffness: A useful tool in the longitudinal follow-up of patients with Fontan circulation
14. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD
15. 253 – The Polyp-Based Resect-And-Discard Strategy: A Prospective Study
16. SAT-288-Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease
17. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease
18. Liver and spleen elastography using supersonic shear imaging for the non-invasive diagnosis of cirrhosis severity and oesophageal varices
19. MR relaxometry in chronic liver diseases: Comparison of T1 mapping, T2 mapping, and diffusion-weighted imaging for assessing cirrhosis diagnosis and severity
20. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®)
21. Non-invasive assessment of liver fibrosis with impulse elastography: Comparison of Supersonic Shear Imaging with ARFI and FibroScan®
22. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations
23. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)
24. Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe
25. Screening for liver fibrosis by using FibroScan® and FibroTest in patients with diabetes
26. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan®
27. High-Dose Pegylated Interferon-α and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial)
28. Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients With Chronic Hepatitis C
29. Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study
30. Intervention brève en alcoologie
31. Interpreting liver stiffness in the cirrhotic range
32. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: Comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores
33. Comment gérer les comorbidités en hépatologie ? Vers une médecine plus globale
34. Hepatitis B virus genotypes : a retrospective survey in Southwestern France, 1999-2004
35. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: Long-term follow-up of 196 patients (4535 patient-years)
36. Effect of Ribavirin in Genotype 1 Patients With Hepatitis C Responding to Pegylated Interferon Alfa-2a Plus Ribavirin
37. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
38. Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients
39. Quality assurance program in a digestive endoscopy unit: Indicators elaboration and effectiveness evaluation of undertaken actions
40. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C
41. Non-steroidal anti-inflammatory drugs and variceal bleeding: a case-control study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.